How is argireline dosed?

Concentrations and schedules in trials
TrialConcentration and schedulePeopleLength
Wang 2013 trial, peri-orbital wrinkles, against placebo (3:1)Concentration not stated; twice daily3604 weeks
Blanes-Mira 2002 studyOil/water emulsion containing 10% of the hexapeptide4Healthy women volunteers, number not stated30 days
Mahidol University trial NCT01381484, periorbital wrinkles, against placebo gel10% gel on the face and periorbital area, twice daily170 healthy women, 35-45 years old3 months
UC Davis trial NCT02597777, oily skin, split face against placebo lotion10% lotion, a pea-sized amount per half face, twice daily5144 weeks
NIH blepharospasm trial NCT00942851, from the day after a botulinum toxin injection, against placebo cream0.005% cream on the eyelids, twice daily624Up to 7 months
NIH blepharospasm dose comparison NCT01750346, against placebo, terminated0.025% and 0.05% cream, twice daily78 enrolled of 24 plannedAt least 3 months planned

A placebo-controlled Mahidol University trial (NCT01381484) of 70 people tested a 10% argireline gel, applied to the face and periorbital area twice daily for 3 months, while the Cosmetic Ingredient Review panel found it safe in cosmetics in present practice at concentrations up to 0.005%.12

Concentrations and schedules in trials

The table is set at the top of the page

The wrinkle studies used 10% on the face or the eye area where a concentration is stated, the UC Davis oily-skin trial used 10% on half the face, and the NIH blepharospasm trials used 0.005%, 0.025% and 0.05% on the eyelids.41567 Among the human trials, the UC Davis trial alone states an amount per application, a pea-sized amount per half face, and no label states one.5

Labels, maker sheets and the safety limit

Searches of DailyMed and ClinicalTrials.gov turned up no drug label or regulator dose for argireline. The Guinama data sheet for the raw-material solution gives 2 to 10%, and the Avenalab sheet gives 0.5 to 5%.89 These are use levels for cosmetic formulators, and none gives a water volume per vial.

The Cosmetic Ingredient Review panel concluded acetyl hexapeptide-8 amide is safe in cosmetics in the present practices of use at concentrations up to 0.005%, and that the data are insufficient to make a determination above 0.005%, a lower figure than the 10% in the wrinkle trials.21

Mixing into a serum

The Guinama sheet says the solution is soluble in water and is to be formulated below 40°C at pH 3 to 8.8 The UC Davis trial diluted the peptide solution to a final 10% in a Cetaphil facial lotion base.5 The maker sheets' percentages refer to the raw-material solution, whose own peptide strength the saved sheets do not state, so no mg per mL is sourced. No label or trial uses a syringe for a topical, so no U-100 marks apply; the units and dosing guide covers injectables.

Storage

The Guinama sheet says to keep the unmixed solution cool, dry, away from sunlight and in a tightly closed container, and the Avenalab sheet says to store its product in the refrigerator.89 None of the sheets gives storage after dilution or in a finished serum.

Frequently asked questions

How long is a course of argireline?

The wrinkle and oily-skin trials ran from 4 weeks (Wang, UC Davis) to 3 months (Mahidol University), and the NIH blepharospasm trial NCT00942851 ran up to 7 months.3516 None of the sources states a cycle or a break between courses.

References

  1. ClinicalTrials.gov. NCT01381484: Argireline in Treatment of Periorbital Wrinkles. 2009. clinicaltrials.gov
  2. PubMed. Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics. 2025. pubmed.ncbi.nlm.nih.gov
  3. PubMed. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. 2013. pubmed.ncbi.nlm.nih.gov
  4. PubMed. A synthetic hexapeptide (Argireline) with antiwrinkle activity. 2002. pubmed.ncbi.nlm.nih.gov
  5. ClinicalTrials.gov. NCT02597777: Topical Acetyl Hexapeptide-8 and the Cosmetic Appearance of Oily Skin. 2016. clinicaltrials.gov
  6. ClinicalTrials.gov. NCT00942851: A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm. 2012. clinicaltrials.gov
  7. ClinicalTrials.gov. NCT01750346: Acetyl Hexapeptide-8 for Blepharospasm. 2016. clinicaltrials.gov
  8. Laboratorios Guinama. 1. guinama.com
  9. Avenalab. Argireline Peptide TDS ENG. avenalab.com
  10. ClinicalTrials.gov. NCT03878381: Investigating the Wrinkle Reduction Potential of a Novel Compounded Skin Care Cream. 2022. clinicaltrials.gov